Gastric Cancer Clinical Trial
Official title:
Stomach and Oesophageal Cancer Study (SOCS)
RATIONALE: Collecting and storing samples of tissue, blood, and saliva from patients with
cancer to test in the laboratory may help the study of cancer in the future.
PURPOSE: This research study is collecting blood and tissue samples from patients with
stomach cancer, esophageal cancer, or gastroesophageal junction cancer, studying them in the
laboratory, and storing them for future studies.
OBJECTIVES:
- To set up a population-based gastric and esophageal cancer cohort with comprehensive
epidemiological, clinical, and pathological data in order to identify novel genetic and
environmental risk factors for these cancers using an association study design.
- To establish a blood-based epidemiological resource with parallel tumor samples on a
population-based series of gastric and esophageal cancer cases.
- Compare any differences in genetic susceptibility genes according to the site of
esophago-gastric cancer (e.g., distal gastric, proximal gastric, or junctional and
esophageal tumors) and the histopathological sub-type.
- Test existing molecular hypotheses and determine whether common genetic variants in
candidate genes predispose to gastric and esophageal cancer by comparing the frequency
of variants in cancer patients with that in controls.
- Generate new hypotheses of genetic and certain environmental determinants, explore the
potential impact on cancer disease risk of a range of environmental factors that can be
measured in plasma (e.g., antibodies to various infective agents, markers of systemic
inflammation, markers of oxidation), and examine gene-environment interactions.
- Refine our understanding of risk factors that are identified (e.g.,chronic Helicobacter
pylori infection and smoking) and examine how these interact with genetic determinants
of disease.
- Define the proportion of gastric cancer incidence attributable to mutations in known
predisposing genes, such as E-cadherin.
- Obtain data on molecular profiles of tumors (mostly paraffin-embedded, rarely frozen)
using dense array technologies, therefore enabling studies of the interaction between
germline polymorphisms and tumor somatic genotype upon tumor behavior, response to
treatment, and patient outcome.
OUTLINE: This is a multicenter study.
Patients and healthy controls complete an epidemiological questionnaire, provide a blood
sample for plasma and genetic analyses, and may also provide a saliva sample. Tumor samples
(in the form of paraffin block material or, in rare cases, frozen) may also be obtained from
the hospital where the patient underwent surgery.
White blood cells are assayed for DNA/RNA isolation to look at genetic variants. DNA is
extracted from saliva to look at genetic variants. Plasma/serum samples are analyzed to look
at proteins and serological markers. Tumor samples are used to review the histology type.
Nucleic acids are extracted from tumor sample sections; retrieval of a small (0.6 mm) core
from each section is used to construct a tissue microarray which are be analyzed by
immunohistochemistry and FISH.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
PROJECTED ACCRUAL: A total of 1,000 patients per cancer (gastric and esophageal) and 2,000
controls will be accrued for this study.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |